C50.829
C50.829 — Malignant neoplasm of overlapping sites of unspecified male breast
Billable / specific codeICD-10-CMunspecified
C50.829 is a billable, specific ICD-10-CM code for malignant neoplasm of overlapping sites of unspecified male breast. It is valid for submission on a claim.
Risk adjustment
C50.829 risk-adjusts. Under the CMS-HCC V28 model it maps to these categories:
- HCC 22 Bladder, Colorectal, and Other Cancers0.363 RAF
- HCC 23 Prostate, Breast, and Other Cancers and Tumors0.186 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C50.829 is named in 57 Medicare coverage policies — 57 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C50.82. If C50.829 is not quite right, the correct code is usually one of these.
Questions about C50.829
- Is C50.829 a billable ICD-10-CM code?
- Yes. C50.829 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C50.829 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of breast (C50).